Exclusive Look At Rafarma Pharmaceuticals, Inc. (RAFA), Burgeoning Russian Pharmaceutical Industry
Seeking Alpha Analyst Since 2008
In a QualityStocks Production released today, Rafarma Pharmaceuticals' management explains the company's world class production facility, manufacturing equipment, scientific developments, and its strategy to become a leading pharmaceutical player in the Russian pharmaceutical industry.
"The target of Rafarma is providing a pharmaceutical market, domestic Russian pharmaceutical market, and foreign pharmaceutical markets with pharmaceutical products of the highest quality at affordable prices," Julia Andryshkova, a member of the board of directors of ZAO Rafarma, says in the interview.
CEO Sergey Brunsnitsyn explains the construction, engineering, maintenance, and capabilities of the plant, as well as its overarching production goals.
"The program aims for developing of modern high-performance industrial and production basis corresponding to the GMP standards that will provide highly competitive domestic products for both internal and external markets," he says.
The video includes interviews from several individuals on the company's management team as well as plant employees.
To watch the entire video, visit videos.qualitystocks.net
For more information on Rafarma, visit rafarma.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.